Health
First-in-human study with novel antisense oligonucleotide proves promising – Medical Xpress
A single intravenous dose of MRG-110, an anti-microRNA drug, significantly reduced miR-92a levels in the blood of healthy humans. Inhibition of miR-92a has shown beneficial effects in animal models, including improved vascularization after myocardial infarcti…
A single intravenous dose of MRG-110, an anti-microRNA drug, significantly reduced miR-92a levels in the blood of healthy humans. Inhibition of miR-92a has shown beneficial effects in animal models, including improved vascularization after myocardial infarction, and accelerated wound healing, according to the peer-reviewed journal Nucleic Acid Therapeutics.
“Based on documented, promising therapeutic potential, locked nucleic acid (LNA)-based anti-miR-92a was further developed and tested in a f…
-
General22 hours agoCan recognising the state of Palestine achieve a two-state solution as Israel continues bombing Gaza?
-
Noosa News16 hours agoCelebrate 200 years of steam trains with a ride on the Rattler
-
Business15 hours agoUp 64% in a month! This unique ASX uranium stock is leading the charge amidst sector-wide rally
-
Noosa News16 hours agoSchool holiday patrols target sand and bitumen